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Abstract
Objective—The OMERACT Filter provides guidelines for the development and validation of 
outcome measures for use in clinical research. The ‘Truth’ section of the OMERACT Filter 
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requires that criteria be met to demonstrate that the outcome instrument meets the criteria for 
content, face and construct validity.
Method—Discussion groups critically reviewed the variety of ways in which case studies of 
current OMERACT Working Groups complied with the ‘Truth’ component of the Filter and what 
issues remained to be resolved.
Results—The case studies showed that there is broad agreement on criteria for meeting the 
‘Truth’ criteria through demonstration of content, face and construct validity; however several 
issues were identified that the Filter Working Group will need to address.
Conclusion—These issues will require resolution in order to reach consensus on how ‘Truth’ 
will be assessed for the proposed Filter 2.0 framework, for instruments to be endorsed by 
OMERACT.
Introduction
The OMERACT Filter provides guidelines for the development and validation of outcome 
measures for use in clinical research. The previous paper described discussions on the 
proposed framework for defining Core Areas as the basis for the selection of Core Outcome 
Domains and hence appropriate Core Outcome Sets for clinical trials. This paper describes 
the second discussion session on the later step of assessing each of the available instruments 
against the criteria for the ‘Truth’ part of the OMERACT Filter: (Fig 1). This OMERACT 
session was deliberately constructed to test whether the new framework builds on 
OMERACT Filter 1.0 and to show how the selection of instruments and assessment of Truth 
would work in practice within the new Filter 2.0 framework. Using case studies from 
different actual OMERACT working groups, participants were able to review the ways in 
which instruments were selected and the Truth Criterion of the Filter 1.0 has been assessed 
and achieved.
A Core Outcome Measurement Instrument Set is defined as: the minimum set of outcome 
measurement instruments that must be administered in each intervention study of a certain 
health condition within a specified setting to adequately cover a corresponding Core Domain 
Set. As depicted, the development process allows core set developers to declare a 
Preliminary Core Outcome Measurement Set when not all Domains are covered by at least 
one applicable measurement instrument. This paper focusses on documenting the Truth 
component of applicability [3rd level down on the left of the figure].
The previous paper focussed on the selection of the Core Domains. Next as can be seen in 
the 2 circles in the Figure above, firstly a literature search is implemented and a list of 
candidate measurement instruments is identified for each Domain and relevant subdomains 
within the 4 Core Areas [Death, Life impact, Resource use, Pathophysiological 
manifestations]. Then, secondly the clinimetric properties of these instruments are assessed 
(Table 1) and one or more candidate instruments selected on the basis of their properties 
[truth, discrimination and feasibility]. As the figure shows, if none of the instruments 
identified in lit search has no foreseeable hope to meet OMERACT criteria in a particular 
disease, a new instrument will need to be developed that meets these Filter criteria for Truth 
[and Discrimination and Feasibility as described in the paper after this].
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This OMERACT 11 session focussed on the ‘Truth’ part of the Filter, i.e. content, face and 
construct validity.
The definitions for different types of validity encompassed within the Truth component [see 
Table 1] remain unchanged from Filter 1.0. However different OMERACT groups have 
used various approaches to satisfy these criteria for the Truth requirement. This workshop 
was held to allow participants to present case studies representative of different methods 
employed by different groups to satisfy these criteria.
A background discussion paper (xx Filter Doc) was prepared for this OMERACT 11 
session.
This second OMERACT Filter 2.0 Session sought to reassure participants that the new 
framework builds on OMERACT Filter 1.0 and to show how the selection on the 
instruments and assessment of Truth would work with the new Filter 2.0, using case studies 
drawn from Working Groups across the spectrum of OMERACT activities. Discussion 
(‘breakout’) groups were invited to critically review how the case study might comply with 
or negate the new Filter 2.0 framework proposal, whether these observations had a more 
general application, and what issues remained to be resolved before consensus could be 
reached. Further formal and informal discussions during the OMERACT 11 meeting 
provided opportunities for clarifications and resolution of many areas of uncertainty before a 
final plenary vote at the last conference session.
Case studies and breakout discussions
Five illustrative case studies [Fatigue/Sleep; Gout; MRI in RA; Polymyalgia Rheumatica; 
Worker Productivity] were presented, each to two breakout groups before a discussion 
among OMERACT 11 delegates. Each group was asked to discuss the following “Do you 
think that the content, face and construct validity concepts apply to what you have heard 
from your Breakout Presentation? Does the Group's work seem practical? Are there issues in 
the content, face and construct validity concepts that the Group has not addressed? If so, 
how could they do this? To what extent are your comments generalisable across 
measurement issues as a whole?”
Plenary report back and discussion
Each breakout group reported the main points from its discussion to a plenary session of all 
participants. While the case studies each brought to light specific issues related to particular 
areas of work (helpful for the OMERACT group working in that area to consider further), 
several common themes emerged. These themes and the broad areas where existing work 
was entirely compatible with the new proposal were further explored during a highly 
participative plenary discussion session, and are summarised in Table 2.
A number of general issues emerged from the breakout group reports and the plenary 
discussion. As in the previous session participants were convinced of the importance of 
appreciating that one should not start to choose Core Sets with the instruments but that there 
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is a two-step process: a)defining Core Domains within the Core Areas, and b) identifying (or 
developing and validating) instruments to include in the Core Outcome set.
• A recurrent theme was the request to provide concrete examples of the extent and 
type of data needed to satisfy the Truth Criterion within the new Filter 2.0 
Framework.
• Many existing instruments, e.g. questionnaires such as the SF36, relate to more 
than one Core Area
• Different groups used different approaches to establishing Truth
• The role and involvement of patients in each stage differed
• The technical details of construct validity are difficult for anyone without a training 
in statistics to be expected to understand, and the general OMERACT participants 
need to be reassured these have been checked by an expert
• Criterion validity is usually not applicable for the instruments being validated as 
most are measuring constructs for which no gold standard is available.
• When several instruments are available, how should decisions be made on which 
has the best ‘truth’? Do we need to have a head to head comparison of instruments 
to decide? These bulleted points above will be followed up by the Filter 2.0 
Working Group.
Summary and conclusions
This OMERACT session was deliberately constructed to show how the new framework 
builds on OMERACT Filter 1.0 and to show how the selection of instruments and 
assessment of Truth would work in practice within the new Filter 2.0 framework. Using case 
studies from different working groups, participants were able to review the ways in which 
instruments were selected and the Truth Criterion of the Filter 1.0 has been assessed and 
achieved. In the vote at the end over 90% of participants endorsed this part of the new Filter 
2.0 framework. They expressed a clear need to develop explicit guidelines on how to 
document sufficient validity for an instrument to pass the Truth requirement of the Filter, 
with examples. The case studies discussed during the OMERACT 11 session will form the 
basis for such material which will be included in the OMERACT Handbook which is under 
development.
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Fig 1. 
Development of a Core Outcome Measurement Set from a Core Domain Set.
Tugwell et al. Page 6
J Rheumatol. Author manuscript; available in PMC 2014 October 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tugwell et al. Page 7
Table 1
Types of validity relevant to assessing “Truth”
Type of validity Meaning
Face validity Credibility: Is the instrument credible?
Content validity Comprehensiveness: Does the instrument (or group
of instruments) sufficiently sample the core domain
addressed?
Construct validity Do the results of the instrument agree with expected
results of other instruments measuring the same
construct/concept?
Criterion validity Difficult in this setting. The only external criterion
available is long term outcome.
Does the result of the instrument predict or correlate
with long term outcome (e.g. death, disability,
perhaps X-ray damage)
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Table 3
Main issues emerging from breakout groups in establishing face, content and construct validityrequiring 
clarification and resolution for Filter 2.0.
Some general issues Are the criteria the same for each domain within instruments that
cross domains?
When and how to involve patients (especially in face and content)?
When and how to involve other stakeholders in addition to patients,
clinicians , researchers and approval agencies – e.g. general public,
policy makers, economists, the press
Some process issues Can one get some Core Domain Instruments approved before
others? e.g. Does core set development come to a stop if one or more
Core Domains does not have a validated instrument?
There should be provision for updating or revision of Core Outcome
sets as further data accumulate.
Face validity How many of each stakeholder group need to assess this?
Content validity Should we always match subdomains and /or link to the ICF as
external framework for ‘what to measure’.
Construct validity Should there be a standard set of constructs?
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